Takeda Pharmaceutical Company Limited (FRA:TKDA)
Germany flag Germany · Delayed Price · Currency is EUR
13.80
+0.20 (1.47%)
At close: Jan 27, 2026

FRA:TKDA Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
112,926107,928144,067317,017230,059376,005
Depreciation & Amortization
721,412720,982695,415664,400583,151559,671
Other Amortization
25,61440,41432,587---
Loss (Gain) From Sale of Assets
-19,041-5,703-1,780-6,797-7,174-232,102
Asset Writedown & Restructuring Costs
163,092106,529150,01764,39454,51525,452
Loss (Gain) From Sale of Investments
-1,798-60220,7573,991-11,19559,277
Loss (Gain) on Equity Investments
2,6033,986-6,4738,63015,367-76
Stock-Based Compensation
70,69172,86770,87160,67243,37437,663
Other Operating Activities
161,78470,153-133,114-109,887116,403-90,740
Change in Accounts Receivable
13,496-58,95915,10475,127127,294-9,316
Change in Inventory
-84,985-34,973-115,743-79,155-46,14825,978
Change in Accounts Payable
2,381-7,118-9,895-84,804125,15736,620
Change in Other Net Operating Assets
20,88741,678-145,46963,568-107,698222,499
Operating Cash Flow
1,189,0621,057,182716,344977,1561,123,1051,010,931
Operating Cash Flow Growth
6.78%47.58%-26.69%-13.00%11.10%50.94%
Capital Expenditures
-178,434-200,795-175,420-140,657-123,252-111,206
Sale of Property, Plant & Equipment
6,432788,6069621,81546,453
Cash Acquisitions
-----49,672-
Divestitures
43,77620,55619,9597,95828,196530,388
Sale (Purchase) of Intangibles
-261,934-147,046-305,310-493,032-62,785-125,262
Investment in Securities
47,949-11,4071,25512,1038,58062,008
Other Investing Activities
11,406-28,446-12,9525,564-1,007-8,851
Investing Cash Flow
-330,805-367,060-463,862-607,102-198,125393,530
Short-Term Debt Issued
-27,490277,00040,000--
Long-Term Debt Issued
-1,024,460100,00075,000249,3341,179,515
Total Debt Issued
553,5501,051,950377,000115,000249,3341,179,515
Short-Term Debt Repaid
-----2-149,043
Long-Term Debt Repaid
--1,366,264-375,487-400,071-849,809-1,690,976
Total Debt Repaid
-730,361-1,366,264-375,487-400,071-849,811-1,840,019
Net Debt Issued (Repaid)
-176,811-314,3141,513-285,071-600,477-660,504
Repurchase of Common Stock
-101,581-51,860-2,326-26,929-77,531-2,141
Common Dividends Paid
-312,852-302,498-287,188-279,416-283,665-283,357
Other Financing Activities
-129,876-82,753-66,415-117,732-108,592-142,352
Financing Cash Flow
-721,120-751,425-354,416-709,148-1,070,265-1,088,354
Foreign Exchange Rate Adjustments
23,673-11,38526,20422,92928,75812,501
Net Cash Flow
160,810-72,688-75,730-316,165-116,527328,608
Free Cash Flow
1,010,628856,387540,924836,499999,853899,725
Free Cash Flow Growth
10.20%58.32%-35.34%-16.34%11.13%65.80%
Free Cash Flow Margin
22.64%18.69%12.69%20.77%28.02%28.14%
Free Cash Flow Per Share
630.67533.47342.28532.85633.95571.78
Cash Interest Paid
116,960112,984100,375108,555108,207107,350
Cash Income Tax Paid
156,738150,413202,039185,966140,423201,687
Levered Free Cash Flow
536,711735,617119,407480,297929,111783,893
Unlevered Free Cash Flow
618,266817,171191,527553,4051,005,631865,646
Change in Working Capital
-48,221-59,372-256,003-25,26498,605275,781
Source: S&P Global Market Intelligence. Standard template. Financial Sources.